Rapport Therapeutics (RAPP) closed at $29.37 on October 20, 2026, up 2.7% from the previous close, on volume of 5,858,703 shares (30-day average 410,843).
Data as of October 20, 2026.
Analysts’ Top NA Picks: Rapport Therapeutics, Inc. (RAPP), SpaceX (SPCX)
TipRanks (Wed, 21-Oct 6:50 AM ET)
Rapport’s RAP-219 posts statistically significant Week 3 mania improvements in Phase 2 bipolar trial
Market Chameleon (Tue, 20-Oct 3:06 AM ET)
Rapport climbs as lead asset succeeds in mid-stage trial for bipolar mania
Seeking Alpha News (Tue, 20-Oct 6:53 AM ET)
Rapport Therapeutics Reports Positive Phase 2 Bipolar Mania Data
TipRanks (Tue, 20-Oct 6:30 AM ET)
Globe Newswire (Tue, 20-Oct 6:00 AM ET)
Wells Fargo Sticks to Its Buy Rating for Rapport Therapeutics, Inc. (RAPP)
TipRanks (Sun, 18-Oct 8:45 AM ET)
Rapport Therapeutics to Participate in Upcoming Investor Conferences
Globe Newswire (Wed, 2-Sep 7:00 AM ET)
Globe Newswire (Mon, 24-Aug 7:00 AM ET)
Rapport Therapeutics Reports Second Quarter 2026 Financials and Provides Business Update
Globe Newswire (Wed, 5-Aug 7:00 AM ET)
RAPP Stock Jumps 152.86% Ahead of RAP-219 Phase 2a Results—Is the Market Pricing in a Breakthrough?
Market Chameleon (Mon, 8-Sep 6:56 AM ET)
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.
Rapport Therapeutics trades on the NASDAQ stock market under the symbol RAPP.
As of October 21, 2026, RAPP stock price climbed to $29.51 with 32,692 million shares trading.
RAPP has a beta of 1.75, meaning it tends to be more sensitive to market movements. RAPP has a correlation of 0.16 to the broad based SPY ETF.
RAPP has a market cap of $1.42 billion. This is considered a Small Cap stock.
Last quarter Rapport Therapeutics reported $0 in Revenue and -$1.19 earnings per share. This fell short of revenue expectation by $-4 million and missed earnings estimates by -$.22.
The top ETF exchange traded funds that RAPP belongs to (by Net Assets): VTI, IWM, VXF, IWO, IBB.
RAPP has underperformed the market in the last year with a price return of +11.7% while the SPY ETF gained +15.9%. RAPP has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -26.6% and -5.3%, respectively, while the SPY returned +4.0% and -1.1%, respectively.
RAPP support price is $28.08 and resistance is $30.66 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RAPP shares will trade within this expected range on the day.
